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Abstract
Background: In the vasculature, Notch signaling functions as a downstream effecter of Vascular Endothelial
Growth Factor (VEGF) signaling. VEGF regulates sprouting angiogenesis in part by inducing and activating matrix
metalloproteases (MMPs). This study sought to determine if VEGF regulation of MMPs was mediated via Notch
signaling and to determine how Notch regulation of MMPs influenced endothelial cell morphogenesis.
Methods and Results: We assessed the relationship between VEGF and Notch signaling in cultured human
umbilical vein endothelial cells. Overexpression of VEGF-induced Notch4 and the Notch ligand, Dll4, activated
Notch signaling, and altered endothelial cell morphology in a fashion similar to that induced by Notch activation.
Expression of a secreted Notch antagonist (Notch1 decoy) suppressed VEGF-mediated activation of endothelial
Notch signaling and endothelial morphogenesis. We demonstrate that Notch mediates VEGF-induced matrix
metalloprotease activity via induction of MMP9 and MT1-MMP expression and activation of MMP2. Introduction of
a MMP inhibitor blocked Notch-mediated endothelial morphogenesis. In mice, analysis of VEGF-induced dermal
angiogenesis demonstrated that the Notch1 decoy reduced perivascular MMP9 expression.
Conclusions: Taken together, our data demonstrate that Notch signaling can act downstream of VEGF signaling to
regulate endothelial cell morphogenesis via induction and activation of specific MMPs. In a murine model of VEGF-
induced dermal angiogenesis, Notch inhibition led to reduced MMP9 expression.
Background
Angiogenesis, the formation of new blood vessels from
existing vasculature, is a multi-step process that plays a
central role in embryogenesis and pathological phenom-
ena. Vascular EndothelialG r o w t hF a c t o r( V E G F )i sa
key regulator of angiogenesis and is important for the
degradation of extracellular matrix (ECM), as well as the
subsequent proliferation, migration, and survival of
endothelial cells. ECM components, including fibrins,
collagens, and laminins, form a lamina around existing
vasculature that must be degraded in order to form new
vessels.
VEGF signaling via VEGFR-2 induces the expression
of endothelial cell-derived matrix metalloproteases
(MMPs), including MMP2 [1], MMP9 [2], and MT1-
MMP [3], which degrade the matrix to allow for
endothelial sprouting. MMPs are thus essential for
angiogenesis, and their loss from either endothelium or
inflammatory cells has been associated with severe
angiogenic defects. At the same time, increased MMP
activity has significant vascular consequences. MMPs
are antagonized by Tissue Inhibitors of Matrix Metallo-
proteases (TIMPs), and a pathological increase in
endothelial MMP over TIMP activity has been proposed
to contribute to vessel wall thickening, abdominal aortic
aneurysm formation, varicose veins, hypertension and
preeclampsia [4-6]. MMPs are not, however, strictly
proangiogenic; other more recently elucidated functions
of this protein family include the mediation of vascular
regression, as well as the generation of ECM fragments
with antiangiogenic properties.
MMP2 and MMP9 belong to the class of gelatinases
with collagen and fibrin as substrates and are expressed
as inactive pro-proteins. MMP2 and MMP9 are pro-
cessed to activate their metalloprotease activity. MT1-
MMP is a member of the membrane associated or
membrane-type MMPs [7-9]. In the vasculature, MT-
MMPs are thought to be involved in the localized
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bFGF, VEGF, and TGF-beta, processing of pro-MMP2
into an activated MMP2, and degradation of ECM com-
ponents including collagens and fibrins [10,11]. MT1-
MMP has been shown to be the most potent fibrinolytic
MMP and has a critical role in the creation of channels
in the ECM, into which endothelial cells migrate during
sprouting angiogenesis [12,13]. MT1-MMP function
is also required for proper lumenization of the new
vessel [13].
Notch signaling is an evolutionarily conserved pathway
that regulates cell fate decisions. Notch proteins, Notch
1 through 4, act as receptors and their ligands Jagged
(Jagged-1, 2) and Delta-like (Dll-1, 3, 4), are all trans-
membrane proteins [14]. Upon ligand binding, the cyto-
plasmic domain of Notch is released by proteolytic
cleavage via presenilin/g-secretase [15], translocates to
the nucleus, and interacts with the transcriptional
repressor CSL (CBF1/Su(H)/Lag2), converting it to a
transcriptional activator [16]. An essential role for
Notch signaling in arterial differentiation and vascular
remodeling has been demonstrated by genetic studies of
mice with targeted mutations in either Notch (Notch1
-/-,
and Notch1
-/-;Notch4
-/-), or Notch ligands (Jagged1
-/-
and Dll4
-/+or Dll4
-/-), reviewed in Shawber et al. [14]. In
addition, targeted activation of Notch4 specifically in
endothelial cells disrupted vascular remodeling, resulting
in embryonic lethality [17]. These studies demonstrate
that proper levels of Notch signaling are essential for
patterning of the vasculature during a period of embryo-
nic development that is known to be critically depen-
dent on VEGF [14,18].
Signaling via both VEGF and Notch is indispensable in
vascular development, and it has become evident that
these two pathways are interconnected. Heterozygous
deficiency of Dll4 results in embryonic lethality with
profound vascular defects, including defective arterial
branching from the aorta and arterial regression, pro-
cesses that also depend on VEGF signaling [19-21] sug-
gesting Dll4 and VEGF work in concert. In cultured
human arterial endothelial cells, VEGF, but not bFGF,
induced expression of Notch1 and Dll4 [22]. Further-
more, expression of Dll4 reduced VEGF/VEGFR-2 sig-
naling, likely via downregulation of VEGFR-2 expression
in cultured endothelial cells [23]. A role for Notch sig-
naling in tumor angiogenesis was originally hypothesized
from the observation that VEGF induced Dll4 in the
angiogenic endothelium of tumor xenografts [24] and
blocking Dll4 functions resulted in dysregulated non-
productive angiogenesis [24,25].
In this study, we demonstrate that Notch mediates
VEGF-induced MMP activity in endothelial cells.
A Notch antagonist, called Notch1 decoy, blocked
VEGF activation of Notch/CSL signaling, VEGF-induced
HUVEC morphogenesis on both collagen and fibrin
gels, and VEGF-induced fibrinolysis. Notch signaling
upregulated the expression of MMP9 and MT1-MMP,
and activated MMP2 and MMP9 in endothelial cells.
Accordingly, we found that the Notch1 decoy-mediated
suppression of HUVEC morphogenesis occurred via
inhibition of MMP activity. Finally, Notch1 decoy sup-
pressed endothelial MMP9 expression in an in vivo neo-
vascularization model in mice. These data demonstrate
that Notch directly regulates the endothelial cell
response to VEGF via induction of MMPs.
Methods
Reagents and Expression Vectors (adenovirus/retrovirus)
GM6001 was used at 50 μM (Elastin Products Com-
pany). eACA was used at 10 mM (Sigma). SU5416 is
from Eisai Co. LTD. Notch1 decoy (N1decoy) encodes
the extracellular domain of rat Notch1 (bp 241-4229,
accession# X57405) fused in frame to human IgG Fc, as
described [26]. The constitutively active Notch1 adeno-
virus (N1IC) encodes the cytoplasmic domain of human
Notch1 as described [27]. LacZ, human VEGF
165,a n d
Notch1 decoy cDNAs were engineered into pAdlox,
recombinant adenoviruses generated and stocks pro-
duced as described [28].
Cells and Adenoviral Infections
HUVEC were isolated from human umbilical vein as
described [29] and grown using EGM-2 Bullet kit (com-
plete medium, LONZA). Porcine type I collagen is from
Nitta Gelatin (Osaka, Japan). Fibrin gels were made by
combining 2 mg/ml fibrinogen (Sigma) and 0.0625 U/ml
thrombin (Sigma) at 4°C, followed by a one-hour incu-
bation at 37°C. Adenovirus infections were as described
[30] at indicated dosage (expressed as MOI - multipli-
city of infection).
Western Blotting
HUVEC were cultured on type I collagen-coated plates
for 5 days in complete media, then starved in serum
free media (SFM, Invitrogen) for 48 hours and cell
lysates collected in TENT buffer (50 mM Tris pH8.0, 2
mM EDTA, 150 mM NaCl, 1% Triton X-100). Westerns
were conducted using an anti-MT1-MMP antibody
(Ab-1, EMD Biosciences).
RT-PCR
HUVEC were seeded on type I collagen gels 2 days after
infection and cultured post-confluence for 5 days before
isolation of total RNA. Total RNA was isolated with RNeasy
mini kit (Qiagen) and First-strand cDNA was synthesized
using SuperScript II™ (Invitrogen). PCR primers were
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Dll4, Notch1, Notch4, MMP2, MMP9, MT1-MMP and
MT2-MMP. PCR used Platinum Taq DNA polymerase
(Invitrogen) and reactions removed at noted cycle number
and product analyzed as described [30]. The following oli-
gos were used for RT-PCR:
MT1-MMP
(5’-CGCTACGCCATCCAGGGTCTCAAA-3’,
5’-CGGTCATCATCGGGCAGCACAAAA-3’),
MT2-MMP
(5’-TCGACGAAGAGACCAAGGAG-3’,
5’-ACTGCCACCAGGAAGAGGTT-3’),
MMP2
(5’-GGGACAAGAACCAGATCACATAC-3’,
5’-CTTCTCAAAGTTGTAGGTGGTGG-3’),
MMP9
(5’-GTATTTGTTCAAGGATGGGAAGTAC-3’,
5’-GCAGGATGTCATAGGTCACGTAG-3’),
GAPDH
(5’-CGGAGTCAACGGATTTGGTCGTAT-3’,
5’-AGCCTTCTCCATGGTGGTGAAGAC-3’).
Luciferase Reporter Assay
HUVEC (3.0×10
5) were infected with adenovirus encod-
ing human VEGF
165(Ad-VEGF) and two days later trans-
fected with Effectene (Qiagen) using 475 ng CSL
luciferase reporter (pGA981-6) [31] 25 ng Renilla lucifer-
ase pRL-SV40 (Promega, Madison, WI) for normalizing
transfection efficiency. The following day Luciferase and
Renilla activity was determined with Dual-Luciferase
®
Reporter Assay System (Promega) and Berthold dual-
injection luminometer. Notch1 decoy effects on VEGF-
activity were evaluated with reporter assays, as above,
after co-transduction of HUVEC with adenovirus encod-
ing Notch1 decoy (Ad-N1ECDFc) and Ad-VEGF.
All assays were performed in triplicate.
HUVEC Morphogenesis Assay
HUVEC morphogenesis was assessed via microscopy
and scored as cells with single or multiple processes
after 5 days of culturing on porcine type I collagen gels,
as described [32]. Adenovirus infections were performed
2 days prior to seeding on collagen gels. GM6001 was
added to medium 1 hr after HUVEC seeding. Cell num-
ber was measured using the Cell Counting Kit-8
(Dojindo Molecular Technologies).
Fibrinolytic Assay
HUVEC were seeded as a monolayer on bovine fibrin
gels in complete medium in 24 well plate. After 5 days,
wells were incubated with 330 ng/ml Thiazolyl Blue
Tetrazolium Bromide (4) (Sigma) for 2 hours. Reagent
was removed and wells documented by digital photogra-
phy. Experiments were performed in triplicate.
Gelatin Zymography
Gelatin Zymography was performed on HUVEC condi-
tioned media as described [33]. HUVEC were infected
with Ad-VEGF at a MOI of 40 or co-infected with Ad-
VEGF and Ad-N1ECDFc each at a MOI of 40. Adeno-
virus encoding LacZ (Ad-LacZ) was used to normalize
infections to 100 MOI. Adenovirus-transduced-HUVEC
were cultured on collagen gels, conditioned medium
collected at indicated days for MMP9 and day 4 for
MMP2.
Dorsal Air Sac (DAS) Assay
The DAS assay was performed as described [34]. KP1/
VEGF121 cells were transduced with Ad-GFP or Ad-
N o t c h 1d e c o ya t6 0M O Ia n dp a c k e di n t oM i l l i p o r e
chambers that were transplanted into a DAS of C57BL/
6 mice. Mice were sacrificed four days after implanta-
tion, and dorsal skin removed and embedded in OCT.
Each group consisted of 3-5 mice, and experiments were
done in duplicate. Dermal cross-sections were immu-
nostained as described [26] with antibodies against
PECAM (Pharminigen) and MMP9 (ABcam) and visua-
lized and imaged by fluorescent microscopy at 20×
magnification.
Results
VEGF-induced HUVEC morphogenesis is mediated by
Notch
Notch functions downstream of VEGF in arterial/venous
specification [35]. We first determined if VEGF induced
Notch signaling in vitro in human umbilical vein
endothelial cells (HUVEC). HUVEC were infected with
increasing MOIs of an adenovirus encoding VEGF-A
(Ad-VEGF). Two days later, a Notch-responsive CSL-
luciferase reporter was introduced by lipofection, and
luciferase activity determined the following day [36].
VEGF-transduced HUVEC exhibited Notch signal acti-
vation in a dose dependent manner, as measured by the
transactivation of the CSL-reporter (Figure 1A). Addi-
tion of SU5416, an inhibitor of VEGF receptor kinases
(VEGFR-1 and VEGFR-2) [37], decreased VEGF-induced
CSL reporter activity (Figure 1B), indicating that the
induction of Notch signaling by VEGF depends on
VEGF receptor activity. To inhibit Notch signaling in
this assay, we infected HUVEC with adenovirus (Ad)-
VEGF and increasing amounts of the Notch antagonist,
Notch1 decoy (Ad-N1decoy) [26,38], which encodes the
extracellular EGF-repeat domain of Notch1 fused to
human Fc. Notch1 decoy inhibited VEGF-induced acti-
vation of Notch signaling in a dose dependent manner
(Figure 1C), demonstrating that VEGF induced ligand-
dependent Notch activation. Consistent with this
hypothesis, VEGF upregulated expression of Notch4 and
the Notch ligand, Dll4 in HUVEC (Additional File 1),
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expression was not significantly altered (Additional
File 1). Our data suggests that VEGF via VEGFR signal
activation induced Notch signaling in HUVEC by upre-
gulating Notch4 and its ligand, Dll4.
When grown on three-dimensional fibrin or collagen
gels, VEGF promotes the formation of cellular exten-
sions that invade the underlying matrix, a phenomenon
termed “HUVEC morphogenesis” [39,40]. To determine
if Notch acts downstream of VEGF-induced morpho-
genesis, HUVEC were transduced with Ad-VEGF or Ad-
LacZ with or without Ad-Notch1 decoy. Three days
after seeding on type I collagen gels, HUVEC were
scored for the presence of cellular extensions and cell
number determined. VEGF promoted HUVEC morpho-
genesis on collagen gels (Figure 2A), consistent with
previous reports [26,32,39,40]. The number of HUVEC
with cellular extensions was dependent on the dose of
Figure 1 VEGF activated Notch signaling in HUVEC. A) HUVEC were transduced with increasing amounts of Ad-VEGF as indicated, and
Notch/CSL reporter activity determined. B) The VEGFR inhibitor (SU5416) perturbed Notch signal activation downstream of VEGF. HUVEC were
transduced with Ad-VEGF at 40 MOI and increasing amounts of SU5416 added to HUVEC prior to determining CSL reporter activity. C) Notch1
decoy blocked VEGF-induced Notch signal activation. HUVEC were transduced with Ad-VEGF at 20 MOI and increasing amounts of Ad-Notch1
(N1) decoy as indicated. Ad-LacZ was added to transductions to normalize the MOI between conditions. Notch/CSL reporter luciferase data are
represented as fold induction relative to Ad-LacZ controls. Experiments were performed in triplicate, and data of a representative experiment
presented.
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In this assay, adenoviral co-transduction of Notch1
decoy with VEGF inhibited VEGF-induced HUVEC
morphogenesis, with a nominal effect on proliferation
(Figure 2A, C). Thus, Notch mediates VEGF-induced
HUVEC morphogenesis on type I collagen and fibrin
gels (Figure 2 and data not shown).
Notch mediates VEGF-induced fibrinolysis
We next determined if VEGF-mediated ECM degrada-
tion occurred via a Notch dependent mechanism.
HUVEC were infected with Ad-LacZ or Ad-VEGF with
or without Ad-Notch1 decoy and seeded on top of fibrin
gels. Six days later, the fibrin gels were incubated with
Thiazolyl Blue Tetrazolium Bromide and visualized.
Expression of VEGF resulted in the complete degradation
of the fibrin gel (Figure 3A). Co-expression of Notch1
decoy with VEGF blocked the fibrinolysis, suggesting that
Notch mediates VEGF-induced fibrinolysis in HUVEC.
Notch regulates VEGF-induced matrix metalloprotease
activity
The gelatinases MMP2 and MMP9 function to degrade
both fibrin and collagen matrices produced by endothelial
Figure 2 VEGF-dependent HUVEC morphogenic changes are mediated by Notch. A) HUVEC were transduced with Ad-LacZ or Ad-VEGF,
with or without Ad-Notch1 (N1) decoy at 40 MOI. Ad-LacZ was used to normalize MOI to 80. VEGF induced HUVEC morphogenesis (lower left
panel) that was blocked by N1 decoy (lower right panel). B) Quantification of Ad-VEGF-induced morphogenesis, measured as numbers of HUVEC
with cellular extensions. HUVEC were transduced with increasing amounts of Ad-VEGF as indicated and Ad-LacZ was used to normalize MOI to
40. C) N1 decoy blocked VEGF-induced HUVEC morphological changes without affecting total cell number. HUVEC were transduced with Ad-
VEGF at 40 MOI and increasing amounts of Ad-N1 decoy as indicated. Ad-LacZ was used to normalize the MOI to 100. Experiments were
performed in triplicate, and data of a representative experiment presented.
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were transduced with Ad-VEGF, Ad-N1decoy or both at 40 MOI and Ad-LacZ was used as a control and to normalize the MOI to 80.
Transductants were seeded on fibrin gels and fibrin degradation determined after 5 days. B) N1decoy blocked VEGF-induced MMP2 activation.
HUVEC were transduced with Ad-VEGF at 20 MOI and increasing amounts of Ad-N1decoy as indicated. Ad-LacZ was used as a control and to
normalize the MOI to 80. Four days post-infection, supernatants were collected and subjected to gelatinase zymography. C) N1 decoy blocked
VEGF-induced expression and activation of MMP9. HUVEC were transduced with Ad-VEGF at 40 MOI, with or without Ad-N1decoy at 40 MOI and
Ad-LacZ was used as a control and to normalize the MOI to 80. Supernatants from transduced HUVEC were collected at 2, 4, 6, and 8 days post-
infection and subjected to gelatinase zymography. D) Cross-section of skin from DAS assay stained for PECAM (red) and MMP9 (green). White
boxes highlight the large vessels within the subcutaneous adipose depot. Yellow boxes highlight the capillaries within the dermal smooth
muscle cell layer. Representative photographs are shown.
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vation of MMPs, such as MMP2 and MMP9 [42]. As
Notch signaling mediated VEGF-induced HUVEC mor-
phogenesis, we determined if the induction of MMP2 and
MMP9 activity by VEGF was mediated by Notch. HUVEC
were infected with Ad-VEGF and increasing amounts of
Ad-Notch1 decoy, and conditioned media was used in
zymographic analysis. After four days, the level of MMP2
pro-form was unchanged, while VEGF converted MMP2
to an active form (Figure 3B). VEGF-induced MMP9 activ-
ity 4 days post-transduction, and this activity increased
over the following four days (Figure 3C). The VEGF-
mediated MMP activation we observed was consistent
with previous reports [42]. To examine the role of Notch
in the VEGF induced MMP activities, we assessed MMPs
after expression of the Notch1 decoy. Co-expression of
VEGF with Notch1 decoy inhibited the activation of
MMP2 and blocked the transcriptional induction and bio-
chemical activation of MMP9 by VEGF (Figure 3B, C).
Thus, VEGF activated MMP2 and MMP9 gelatinase activ-
ity by a Notch-dependent mechanism.
To determine if Notch influenced MMP9 expression
during VEGF-induced angiogenesis, we evaluated the
expression of MMP9 in vivo using a dorsal air sac angio-
genesis (DAS) model [34]. In the DAS model, a chamber
containing VEGF-expressing KP1 cells is implanted in the
air sac under the dorsal skin. VEGF is released from the
chamber and induces neo-angiogenesis in the overlying
skin. Using this model, we have previously demonstrated
that Notch1 decoy perturbed VEGF-driven angiogenesis
and suppressed endothelial VEGFR-1 expression [43].
To evaluate MMP9 expression in this model, cross-
sections of skin from DAS assays using either control
VEGF/Fc- or VEGF/Notch1 decoy-expressing KP1 cells
were co-immunostained with antibodies against MMP9
and the endothelial cell marker PECAM. In the control
Fc-expressing tissues, MMP9 expression was observed
around the vessels within both the smooth muscle cell
layer and subcutaneous fat depot (Figure 3D). In the
Notch1-decoy DAS tissues, there was a reduction in
PECAM staining indicating reduced vasculature, as we
previously reported [26]. We also observed a loss of
endothelial-associated MMP9 expression in the Notch1
decoy-expressing DAS tissues relative to Fc control tissue.
Thus, we demonstrate that blocking Notch signaling
downstream of VEGF suppressed endothelial MMP9
expression in vivo.
Notch signaling induces MMP9 and MT1-MMP expression
in HUVEC
Since inhibition of Notch signaling abrogated VEGF induc-
tion of MMP2 and MMP9 activity, we next examined
whether Notch activation upregulated the expression of
MMP2 and MMP9 in HUVEC. HUVEC were infected with
an adenovirus encoding a constitutively active cytoplasmic
form of Notch1 (N1IC), RNA isolated and RT-PCR per-
formed for MMP2, MMP9, and GAPDH. Notch1 activation
upregulated MMP9 transcripts (Figure 4A). Though we
found that Notch1 decoy blocked VEGF from activating
MMP2 (Figure 3B), increased Notch1 signaling paradoxi-
cally suppressed MMP2 transcript levels (Figure 4A). On
the cell surface, MMP2 is activated by membrane-type
MMPs (MT-MMPs) [7]; therefore, we determined if Notch
signaling altered the expression of MT-MMPs, MT1-MMP
and MT2-MMP. Expression of the activated form of
Notch1 upregulated both MT1-MMP transcripts and pro-
tein, but had no affect on MT2-MMP (Figure 4B).
Next, we asked whether Notch activity is required for
the VEGF-induction of MMP9 and MT1-MMP. Ectopic
expression of VEGF increased both MMP9 and MT1-
MMP transcripts (Figure 4C). Co-infections of Ad-
Notch1 decoy with Ad-VEGF suppressed the expression
of both MMP9 and MT1-MMP transcripts. Taken
together, these data demonstrate that Notch1 activation
increased MMP2 and MMP9 activity. Thus, Notch func-
tions downstream of VEGF to regulate MMPs via dis-
tinct mechanisms; Notch upregulated MMP9 activity at
the transcriptional level, while it regulated MMP2 activ-
ity at the cell surface via the induction of MT1-MMP.
Notch-induced HUVEC morphogenesis is mediated by
MMPs
Since VEGF-induced HUVEC morphogenesis requires
Notch signal activation, we determined whether Notch
mediates this process via MMP activation. HUVEC were
transduced with Ad-LacZ or Ad-N1IC and seeded on
type I collagen or fibrin gels. After 7 days, the presence
of HUVEC with cell extensions was evaluated and quan-
tified. We used an adenovirus that co-expressed N1IC
and GFP to visualize the cells expressing the activated
form of Notch1. Notch1 activation induced HUVEC
morphological changes (Additional File 2), similar to
that observed for ectopic VEGF (Figure 2A). In this
assay, Notch1 functioned in a cell autonomous fashion,
as Notch-activated cells (identified as GFP positive cells)
displayed cellular extensions when compared to GFP
negative cells. Moreover, the number of HUVEC under-
going morphological changes increased with higher
doses of Ad-N1IC adenovirus (data not shown). Using
this assay, we asked if Notch promoted HUVEC mor-
phogenesis via the induction and activation of MMPs.
Ad-LacZ and Ad-N1IC-transduced HUVEC were seeded
on either type I collagen or fibrin gels and the MMP
inhibitor GM6001 introduced to the media. GM6001 is
an inhibitor that targets multiple MMPs, including
MMP2, MMP9, and MT1-MMP [44]. Notch-mediated
HUVEC morphogenesis was inhibited by GM6001 when
assayed on either collagen (Figure 5A, B) or fibrin gels
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pathway, we introduced the serine-protease inhibitor,
eACE, to block this pathway in Ad-infected HUVEC
grown on fibrin gels (Figure 5C, D). The serine-protease
inhibitor did not block Notch induced HUVEC morpho-
genesis, and did not have an additive affect when used
in combination with the MMP inhibitor GM6001
(Figure 5D). Thus, VEGF requires Notch signaling to
regulate both expression and activation of specific
MMPs, and Notch, in turn, utilizes MMP activation to
promote HUVEC morphogenesis.
Discussion
In this study, we describe a new means by which Notch
functions downstream of VEGF to regulate the angiogenic
process. We identified MMPs as novel targets of Notch
signaling in endothelial cells. Our data suggest that VEGF
activates Notch signaling by upregulating the expression
of Dll4 and Notch4, consistent with other reports [22].
Notch1 decoy blocked VEGF-activation of Notch/CSL
signaling, VEGF-induced HUVEC morphogenesis on
collagen and fibrin gels, VEGF-dependent fibrinolysis and
VEGF-induced dermal angiogenesis in vivo.N o t c h
Figure 4 Notch induced MMP9 and MT1-MMP expression downstream of VEGF. A) Transduction of an activated form of Notch1 (N1IC)
induced MMP9 transcripts in HUVEC. RT-PCR analysis of MMP2 and MMP9 compared to control GAPDH. B) Transduction of N1IC induced MT1-
MMP. RT-PCR analysis of MT1-MMP and MT2-MMP (left panels) compared to control GAPDH (see A). Western analysis of MT1-MMP (right panel).
C) N1decoy blocked VEGF-mediated induction of MMP9 and MT1-MMP determined by RT-PCR; GAPDH serves as a control. HUVEC were
transduced with Ad-VEGF at 40 MOI, with or without Ad-N1decoy at 40 MOI and Ad-LacZ was used as a control and to normalize the MOI to
80. For RT-PCR experiments, the number of PCR cycles is indicated to the right of the figures. Experiments were performed in triplicate, and data
of a representative experiment presented.
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loprotease activity by upregulating the expression of
MMP9 and MT1-MMP, likely leading to activation of
MMP9 and MMP2. These MMPs function as key regula-
tors of angiogenesis in both physiological and pathological
settings [45]. During angiogenesis, MMP activity functions
to promote ECM degradation, lumen formation, the
activation of membrane receptors, and release of ECM/
membrane-associated pro-angiogenic growth factors,
such as VEGF, bFGF and TGF-b [4]. MMPs also have
Figure 5 Notch-induced HUVEC morphogenesis was mediated via its induction of MMPs. A) Notch-induced HUVEC morphogenesis on
collagen was blocked by addition of an MMP inhibitor. HUVEC were transduced with either Ad-LacZ or Ad-N1IC at 40 MOI and seeded on type
1 collagen gels in the absence or presence of 50 μM GM6001. Images are representative of 5 days post-infection. B) Quantification of Ad-N1IC-
induced morphogenesis on collagen, measured as numbers of HUVEC with cellular extensions. C) Notch-induced HUVEC morphogenesis on
fibrin was blocked by addition of an MMP inhibitor, but not a serine-protease inhibitor. HUVEC were transduced with either Ad-LacZ or Ad-N1IC
at 40 MOI and seeded on fibrin gels in the absence or presence of the matrix metalloprotease inhibitor (50 μM GM6001), or the serine-protease
inhibitor, (10 mM eACE). Images are representative of 5 days post-infection. D) Quantification of Ad-N1IC-induced morphogenesis on fibrin.
Experiments were performed in triplicate, and data of a representative experiment presented. NT (No Treatment).
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ing matrix protein fragments that suppress angiogenesis
[46]. Taken altogether, we propose that Notch signaling
functions downstream of VEGF to affect angiogenesis in
part by inducing endothelial cell localized matrix metallo-
protease activity.
Pericellular matrix metalloproteases regulate the local
availability of bioactive angiogenic factors, such as VEGF
and bFGF. It has been proposed that matrix metallopro-
teases function to increase VEGF activity to promote
pathological angiogenesis during tumorigenesis [42].
Consistent with this hypothesis, deletion of MMP9 in a
mouse model of pancreatic b-cell carcinoma, Rip1Tag2,
suppressed tumor progression [47]. In these mice, the
level of VEGF was unaltered, but mobilization of VEGF
from the extracellular matrix was inhibited. Thus,
endothelial upregulation of MMP9 by Notch may lead
to the localized release and activation of matrix-bound
growth factors.
Besides its role in processing and activating MMP2,
MT1-MMP also functions to degrade the surrounding
fibrin matrix during physiological and pathological angio-
genesis. The breakdown of the local fibrin matrix is
essential in the initiation and propagation of angiogenic
responses, and generates a provisional matrix that can
sustain the formation of nascent vessels during wound
healing, inflammation and tumor growth. MT1-MMP
localizes at the leading edge of migrating endothelial cells
and is thought to aid in the degradation of the extracellu-
lar matrix to facilitate endothelial cell invasion [48].
Although MT1-MMP may be the most potent fibrinoly-
tic MMP, the gelatinases MMP2 and MMP9 also recog-
nize fibrin as a substrate. More recently, Stratman et al
demonstrated that the formation of vascular guidance
tunnels within collagen gels occurred via a MT1-MMP-
dependent proteolytic process and that these tunnels
become conduits for EC motility in sprouting angiogen-
esis [13] Thus, the induction of MT1-MMP by Notch
may lead to the activation of MMP2 that together with
MT1-MMP and MMP9 promote extracellular matrix
degradation and endothelial cell morphogenesis.
MT1-MMP activity has also been shown to be critical
for endothelial migration during sprouting angiogenesis
[42,49]; however Notch signal activation is a potent inhibi-
tor of endothelial cell migration [50,51], which suggests
that Notch signaling has both anti- and pro-angiogenic
functions. Thus, Notch may have an early pro-angiogenic
function in the induction and activation MMPs to pro-
mote the degradation of the pericellular matrix, but it sub-
sequently needs to be turned off to allow for endothelial
cell migration and tube formation to progress. MT1-MMP
activity has also been shown to be critical for endothelial
lumen formation [13]. Taking this finding into considera-
tion, Notch may be turned off in tip cells and induces
MMPs in stalk cells, which may be important for remodel-
ing the matrix during the process of lumen formation. The
latter model fits well with our current understanding of
Notch function in the restriction of endothelial sprouting
by blocking tip cell differentiation [52].
The molecular mechanism by which Notch regulates
MMP9 and MT1-MMP expression in HUVEC is
unclear. In lung metastases of Rip1Tag2 mice, MMP9
expression, within the endothelium, was regulated by
VEGFR-1 [53]. Since Notch induces VEGFR-1 expres-
sion in endothelial cells [43,54], VEGFR-1 signaling may
mediate the induction of MMP9 by Notch. However,
Notch1 has also been shown to regulate the expression
and activation of MMP9 through NF-B in pancreatic
cancer cells [55], suggesting that the regulation of
MMP9 expression and activity in endothelial cells by
Notch may be mediated by NF-B signaling. Finally, the
activation of MMP9 at the cell surface is dependent on
the uPA/plasmin pathway. In human prostatic cancer
cells, knock-down of Notch1 resulted in a downregula-
tion of MMP9 and uPA and its receptor, uPAR [56].
From our data it is unclear whether Notch regulates
MMP9 solely at the level of transcription, and the possi-
bility remains that it may regulate the uPA/plasmin
pathway to activate MMP9 at the cell surface. This is a
subject of future investigation.
We propose that Notch activates MMP2 via induction
of MT1-MMP, which is present in its active form at the
cell surface. In the tumor microenvironment, an imbal-
ance may arise from an increase in MMP expression/
activity and a decrease in the expression of the MT-
MMP inhibitors, TIMP-2 or TIMP-3 [4,5]. This imbal-
ance would result in a pro-angiogenic state. A similar
imbalance in MMP/TIMP activity ratio has also been
implicated in aortic aneurysm, varicose veins, hyperten-
sion and preeclampsia [6]. As inhibition of Notch signal-
ing with Notch1 decoy blocked the induction of MMP9
and MT1-MMP transcripts in HUVEC, blocking Notch
signaling in pathological settings may perturb angiogen-
esis and may prove therapeutically useful in the treat-
ment of vascular disorders.
Additional material
Additional file 1: VEGF induced Notch and Notch ligand expression
in HUVEC. HUVEC were transduced with either Ad-LacZ or Ad-VEGF at
40 MOI. Two days later, total RNA was isolated and RT-PCR performed
with PCR primers designed to amplify GAPDH, Notch1, Notch4, Jagged1,
Dll4. Reactions were removed at noted cycle number and product
analyzed as described [30]. Number of PCR cycles is indicated.
Additional file 2: Notch signal activation cell autonomously altered
HUVEC morphology. HUVEC were transduced with an adenovirus which
co-expresses N1IC and GFP at 40 MOI. N1IC/GFP expressing tranductants
were mixed with control HUVEC and cultured on type 1 collagen gels for
7 days. Notch activated cells, identified as GFP positive cells, display
cellular extension, as compared to GFP negative cells.
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